Hims and Hers (HIMS) PT Raised to $61 at Needham

Hims and Hers (HIMS) PT Raised to $39 at Truist Securities

Truist Securities analyst Jailendra Singh raised the price target on Hims and Hers (NYSE: HIMS) to $39.00 (from $24.00) while maintaining a Hold rating.

The analyst comments "We had a post-quarterly call with HIMS to discuss 4Q24 results, puts and takes in weight loss solution outlook,... More

Leerink Partners Reiterates Market Perform Rating on Hims and Hers (HIMS)

Leerink Partners analyst Michael Cherny reiterated a Market Perform rating and $24.00 price target on Hims and Hers (NYSE: HIMS).

The analyst comments "Bottom Line: Fundamentally, HIMS' 4Q'24 results were slightly below what we think were buyside expectations. HIMS beat our/consensus revenue by ~1.2%/~2.2%,... More

Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)

Morgan Stanley analyst Craig Hettenbach reiterated an Equalweight rating and $60.00 price target on Hims and Hers (NYSE: HIMS)

The analyst comments "Weight loss, including personalized GLP-1 and oral meds, was guided to grow above the overall growth rate in 2025. This part of the... More

Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)

Truist Securities analyst Jailendra Singh reiterated a Hold rating and $24.00 price target on Hims and Hers (NYSE: HIMS)

The analyst comments "Bottom Line. HIMS posted 4Q24 results with revenues slightly ahead of consensus and adjusted EBITDA in-line. However, compared to the broader investor expectations, results were below. Interestingly, the majority of beat in the quarter (relative to our estimate)... More

BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $21

BofA Securities analyst Michael Cherny reiterated an Underperform rating and $21.00 price target on Hims and Hers (NYSE: HIMS)

The analyst comments "HIMS 2025 revenue growth guidance embeds a significant level of optimism around two key items: 1) core revenue growth (ex-GLP-1s); and 2) a successful handoff between semaglutide and oral/liraglutide subscriptions into the second half of the... More

BTIG Reiterates Buy Rating on Hims and Hers (HIMS)

BTIG analyst David Larsen reiterated a Buy rating and $85.00 price target on Hims and Hers (NYSE: HIMS).

The analyst comments "On Monday, 2/24/25 AMC, HIMS reported good 4Q:24 results. Revenue of $481.1M +95% y/y exceeded BTIG / consensus estimates of $474M / $470M and adjusted EBITDA... More

Nephron Downgrades Hims and Hers (HIMS) to Hold

Nephron analyst Eric Percher downgraded Hims and Hers (NYSE: HIMS) from Buy to Hold with a price target of $40.00.

For an analyst ratings summary and ratings history on Hims and Hers... More

Hims and Hers (HIMS) PT Raised to $27 at Citi, Maintains Sell 'as we await a better entry point and more details on growth outside GLP-1s'

Citi analyst Daniel Grosslight raised the price target on Hims and Hers (NYSE: HIMS) to $27.00 (from $25.00) while maintaining a Sell rating.

The analyst comments "The focus on HIMS 4Q earnings call (and our follow-up with mgmt.) was on the durability of HIMS weight loss... More

After-hours movers: Zoom, Hims & Hers Health, Tempus AI, and more

After-hours movers:

Zoom (NASDAQ: ZM) fell 2% after guidance missed estimates. Zoom sees Q1 2026 revenue of $1.162-1.167 billion, versus the consensus of $1.175 billion.

Hims & Hers Health (NYSE: HIMS) fell 16% despite results that... More

Hims&Hers Health Q4 earnings fall short of estimates

Investing.com -- Hims&Hers Health Inc (NYSE: HIMS) reported weaker-than-expected fourth-quarter earnings that overshadowed the telehealth company's revenue that topped Wall Street estimates. 

Hims Hers Health fell 13% in recent afterhours trading.

For the three months ended Dec. 31, the company reported... More

Hims & Hers Health, Inc. (HIMS) Misses Q4 EPS by 6c, Revenue Beats, Offers Guidance

Hims & Hers Health, Inc. (NYSE: HIMS) reported Q4 EPS of $0.11, $0.06 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $481.1 million versus the consensus estimate of $469.33 million.

GUIDANCE:

Hims & Hers Health, Inc. sees FY2025 revenue of $2.3-2.4... More

Hims & Hers earnings preview: BofA weighs in ahead of the report

Bank of America (BofA) has raised its estimates on Hims & Hers Health (NYSE: HIMS) stock ahead of the companys earnings report but maintained the Underperform rating.

The bank's analysts point to accelerating contributions from GLP-1 prescriptions as a key revenue driver while also highlighting uncertainties around the sustainability of this segment.

Observed sales grew 104% year-over-year in January, with GLP-1 treatments accounting for approximately 40% of gross online sales, up from an estimated 26% in the fourth quarter.

"Based on the January trend, 1Q25 Online revenue could be $551MM-$574MM (representing 106-114% y/y... More

Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1.1 puts into quarter results and outlook

Hims & Hers Health, Inc. (NYSE: HIMS) February 28 weekly call option implied volatility is at 211, March is at 144; compared to its 52-week range of 47 to 145 into the expected release of quarter results today after the bell.

Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1 put on active volume into quarter results

Hims & Hers Health, Inc. (NYSE: HIMS) February 28 weekly 50 straddle priced for movement of 16% into the expected release of quarter results today after the bell.

Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $24

Piper Sandler analyst Korinne Wolfmeyer reiterated a Neutral rating and $24.00 price target on Hims and Hers (NYSE: HIMS)

The analyst comments "We believe it's best to remain on the sidelines with HIMS following the FDA's announcement this morning that... More

Analysts explain why Hims & Hers stock is crashing today

On Friday, shares of Hims&Hers Health Inc (NYSE: HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE: NVO)'s weight loss and diabetes drugs was ending. Due to this, the sale price and availability of Ozempic and Wegovy are impacted, which disallows Hims and Hers from selling exact replicas of the semaglutide drugs at a lower price.

In response to the news, BofA analyst Allen Lutz... More

Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put amid wide price movement into quarter results

Hims & Hers Health, Inc. (NYSE: HIMS) February 28 weekly call option implied volatility is at 211, March is at 144; compared to its 52-week range of 47 to 145 into the expected release of quarter results after the bell on February 24.

Today's FDA news a 'clear negative' for Hims and Hers (HIMS) - BofA Securities

BofA Securities analyst Michael Cherny reiterated an Underperform rating and $21.00 price target on Hims and Hers (NYSE: HIMS) after the FDA Drug Shortages List indicates that the semaglutide shortage status is Resolved. Semaglutide has been in shortage since 08/23/2022 according to the FDA... More

Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice

By Patrick Wingrove and Bhanvi Satija

(Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.

Shares of Hims & Hers Health, which advertised its compounded versions of weight-loss drugs during the Super Bowl this month, plunged 22% to $52, on a day it announced the purchase of a plant to make the class of drugs that includes Wegovy and Ozempic.

U.S. regulations allow compounding... More

Hims & Hers Health, Inc. (HIMS) Weakness Tied to Report FDA Says Ozempic, Wegovy Shortage Resolved

Hims & Hers Health, Inc. (NYSE: HIMS) Weakness Tied to Report FDA Says Ozempic, Wegovy Shortage Resolved

Hims & Hers Health (HIMS) Acquires Peptide Facility

Hims & Hers Health, Inc., (NYSE: HIMS) the leading health and wellness platform, today announced an acquisition that will further verticalize the companys long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment... More

Hims & Hers Health, Inc. (HIMS) call put ratio 1.2 calls to 1 put into quarter results

Hims & Hers Health, Inc. (NYSE: HIMS) February 28 weekly 66 straddle priced for movement of 20% into the expected release of quarter results after the bell on February 24.

Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1.2 puts on active option volume of 198K contracts

Hims & Hers Health, Inc. (NYSE: HIMS) 30-day option implied volatility is at 129; compared to its 52-week range of 47 to 146. Call put ratio 1 call to 1.2 puts on 198K contracts.